Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omer Koc

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Cardiovascular Revascularization Medicine : Including Molecular Interventions|March 4, 2006
The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivationShyam Bhakta, Ping Hong, Omer Koc
Leukemia & Lymphoma|March 8, 2024
Lenalidomide, rituximab (R<sup>2</sup>), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphomaBrian T Hill, Yanwen Chen, Deepa Jagadeesh, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Cardiovascular Revascularization Medicine : Including Molecular Interventions|March 4, 2006
The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivationShyam Bhakta, Ping Hong, Omer Koc
Leukemia & Lymphoma|March 8, 2024
Lenalidomide, rituximab (R<sup>2</sup>), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphomaBrian T Hill, Yanwen Chen, Deepa Jagadeesh, et al.
Pageof 1